Royce & Associates LP Catalyst Pharmaceuticals, Inc. Transaction History

Royce & Associates LP

$10.5 Billion
Q3 2024

A detailed history of Royce & Associates LP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 2,021,105 shares of CPRX stock, worth $44.3 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares

2,021,105

Previous 2,162,022 6.52%

Holding current value

$44.3 Million

Previous $33.5 Million 19.98%

% of portfolio

0.38%

Previous 0.33%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$15.19 - $21.35 $2.14 Million - $3.01 Million	-140,917 Reduced 6.52%	2,021,105 $40.2 Million
Q2 2024 Aug 13, 2024	BUY	$14.68 - $16.92 $1.15 Million - $1.32 Million	78,009 Added 3.74%	2,162,022 $33.5 Million
Q1 2024 May 13, 2024	BUY	$13.18 - $17.11 $4.49 Million - $5.83 Million	340,939 Added 19.56%	2,084,013 $33.2 Million
Q4 2023 Feb 12, 2024	BUY	$11.78 - $17.29 $1.55 Million - $2.27 Million	131,372 Added 8.15%	1,743,074 $29.3 Million
Q3 2023 Nov 09, 2023	BUY	$11.69 - $15.02 $6.68 Million - $8.59 Million	571,714 Added 54.97%	1,611,702 $18.8 Million
Q2 2023 Aug 07, 2023	BUY	$11.5 - $18.08 $4.88 Million - $7.67 Million	424,020 Added 68.84%	1,039,988 $14 Million
Q1 2023 May 04, 2023	BUY	$14.34 - $21.05 $1.21 Million - $1.77 Million	84,079 Added 15.81%	615,968 $10.2 Million
Q4 2022 May 23, 2023	SELL	$12.25 - $19.5 $1.03 Million - $1.64 Million	-84,079 Reduced 13.65%	531,889 $9.89 Million
Q4 2022 Feb 13, 2023	SELL	$12.25 - $19.5 $1.55 Million - $2.47 Million	-126,658 Reduced 19.23%	531,889 $9.89 Million
Q3 2022 Nov 03, 2022	SELL	$7.06 - $15.52 $10.2 Million - $22.4 Million	-1,441,678 Reduced 68.64%	658,547 $8.45 Million
Q2 2022 Aug 04, 2022	SELL	$6.23 - $8.57 $1.01 Million - $1.39 Million	-161,682 Reduced 7.15%	2,100,225 $14.7 Million
Q1 2022 May 05, 2022	SELL	$5.31 - $8.31 $1.71 Million - $2.68 Million	-321,961 Reduced 12.46%	2,261,907 $18.8 Million
Q4 2021 Feb 07, 2022	SELL	$5.21 - $7.45 $2.2 Million - $3.15 Million	-423,126 Reduced 14.07%	2,583,868 $17.5 Million
Q3 2021 Nov 10, 2021	SELL	$4.85 - $6.04 $324,232 - $403,786	-66,852 Reduced 2.17%	3,006,994 $15.9 Million
Q2 2021 Aug 06, 2021	SELL	$4.29 - $6.05 $754,199 - $1.06 Million	-175,804 Reduced 5.41%	3,073,846 $17.7 Million
Q1 2021 May 10, 2021	BUY	$3.45 - $4.69 $2.91 Million - $3.96 Million	844,521 Added 35.11%	3,249,650 $15 Million
Q4 2020 Feb 08, 2021	BUY	$2.97 - $3.83 $1.84 Million - $2.38 Million	620,239 Added 34.75%	2,405,129 $8.03 Million
Q3 2020 Nov 12, 2020	BUY	$2.97 - $5.08 $1.41 Million - $2.41 Million	474,984 Added 36.26%	1,784,890 $5.3 Million
Q2 2020 Aug 07, 2020	BUY	$3.48 - $5.05 $2.32 Million - $3.36 Million	665,915 Added 103.4%	1,309,906 $6.05 Million
Q1 2020 May 12, 2020	SELL	$2.61 - $5.21 $357,024 - $712,681	-136,791 Reduced 17.52%	643,991 $2.48 Million
Q4 2019 Feb 06, 2020	BUY	$3.67 - $5.7 $2.87 Million - $4.45 Million	780,782 New	780,782 $2.93 Million

Others Institutions Holding CPRX

# of Institutions

325

Shares Held

94.1M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.25B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Account

Royce & Associates LP Catalyst Pharmaceuticals, Inc. Transaction History